SZ 003 - Guangdong ProCapZoom Biosciences
Alternative Names: SZ-003-Guangdong ProCapZoom Biosciences; SZ003 CAR-NK cell therapyLatest Information Update: 20 Aug 2024
At a glance
- Originator Guangdong ProCapZoom Biosciences
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Liver cancer
Most Recent Events
- 13 Aug 2024 Clinical trials in Liver cancer (Late-stage disease) in China (Parenteral) (NCT05845502)
- 06 May 2023 Guangdong ProCapZoom Biosciences plans a clinical trial for Liver cancer (Late-stage disease, Second-line therapy or greater, In adults, In elderly) (Parenteral, Infusion) in May 2023 (NCT05845502)
- 05 May 2023 Preclinical trials in Liver cancer in China (Parenteral)